Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 11Lung Neoplasms 5Breast Neoplasms 2Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 7pembrolizumab 6Radiotherapy 6Cisplatin 6Sunitinib 5Carboplatin 5Paclitaxel 4Thymectomy 3130-nm albumin-bound paclitaxel 3selinexor 2lenvatinib 2fludarabine 2Taxes 2Robotic Surgical Procedures 2Ramucirumab 2Prednisone 2Pemetrexed 2Octreotide 2Nivolumab 2N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2Methylprednisolone 2Imatinib Mesylate 2Etoposide 2Erlotinib Hydrochloride 2Doxorubicin 2Chemoradiotherapy 2Celecoxib 2zimberelimab 1vorolanib 1saracatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thymoma × amrubicin × Clear all
NCT01364727 2019-04-16

A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

Stanford University

Phase 2 Completed
33 enrolled 11 charts
Thoracic

Thymoma, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡